Microbot Adds Second LIBERTY Hospital, Geographic Expansion Begins

What happened

Microbot Medical announced its second hospital adopter for the LIBERTY endovascular robotic system, a multi-hospital network in North Carolina, expanding beyond the initial Emory site. This validates early commercial traction and widens geography into the Southeast. However, the company still lacks disclosed revenue, procedure volumes, or evidence of recurring disposable usage. The DeepValue report maintains a WAIT rating, stating that meaningful proof requires at least 10 paying sites with documented utilization. This news is incrementally positive but does not alter the fundamental risk of commercialization failure or the need for further dilutive financing.

Implication

If Microbot can continue adding hospitals and demonstrate growing disposable pull-through, the bull case of $4.00 becomes more plausible. However, investors should wait for evidence of at least 10 paying sites and recurring revenue before committing capital. The second adoption is a step in the right direction but insufficient to justify a rating upgrade.

Thesis delta

The thesis shifts slightly positive as geographic expansion begins, reducing single-site dependency risk. However, the WAIT rating remains unchanged because the threshold for a rating increase—disclosure of ≥10 paying hospitals with documented disposable usage—is still far off. The core risks of dilution and slow adoption persist.